Assessment of the efficacy and safety of olaparib monotherapy versus physicians choice chemotherapy in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. (OlympiAD) - AstraZeneca (2013)
last access: 01.03.2017